Table 3 Studies reporting on patients undergoing liver resection for metastatic Wilms’ tumor *Outcome only refers to 22 patients with resection of LM during primary tumor operation vs. 74 without primary resection of LM. No results for the subgroup of 25 patients with resection of LM available. Abbreviations: CR = case report; CS = Case series, EFS = event-free survival, M = metastasis; MC = multi-center, meta = metachronous liver metastases, OncReg = oncological study group registry, ROS = retrospective observational study, SC = single-center, sync = synchronous liver metastases, X = unknown
Authors | Study Type | Year of Publication | Recruitment period | Median age (SD) | Patients with WTLM | Concurrent pulmonary M | Outcome of WTLM Patients | Group A: LR | Outcome group A | Group B: no LR | Outcome group B |
|---|---|---|---|---|---|---|---|---|---|---|---|
Filler et al. | CS | 1969 | 1963-1968 | 4.4y | 2 sync: 0 meta: 2 | 1/2 (50%) | Survival in 2/2 (100%) | 2 | Survival in 2/2 (100%) | 0 | - |
Foster | CS | 1978 | 1947-1978 | - | 15 Sync: X meta: 2+X | Unclear | Survival in 10/15 (67%) | 15 | Survival in 10/15 (67%) | 0 | - |
Edwards et al. | CS | 1990 | 1978-1987 | 10y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Rao et al. | CR | 1992 | - | 8y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Goering et al. | CR | 2002 | - | - | 1 sync: 0 meta: 1 | Unclear | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Patel et al. | CR | 2003 | - | 0.8y | 1 sync: 0 meta: 1 | 0/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Su et al. | ROS-SC | 2007 | 1988 - 2005 | 6.2y (7.1) | 3 sync: 1 meta: 2 | 1/3 (33%) | Survival in 0/3 (0%) | 3 | Survival in 0/3 (0%) | 0 | - |
Fuchs et al. | ROS-OncReg | 2008 | 1994-2004 | 6.5y (8.6) | 45 sync: 29 meta: 16 | 28/45 (62%) | Survival in 24/45 (53%) | 21 | Survival in 12/21 (57%) | 24 | Survival in 12/24 (50%) |
Ehrlich et al. | ROS-OncReg | 2009 | 1986-2002 | - | 96 sync: 96 meta: 0 | 62/96 (65%) | - | 25 | 5-year EFS 86%* | 71 | 5-year EFS 68%* |
Dressler et al. | CR | 2010 | - | 9y | 1 sync: 0 meta: 1 | 1/1 | Survival in 1/1 | 1 | Survival in 1/1 | 0 | - |
Aronson et al. | ROS-SC | 2012 | 2002-2010 | 3.8y (3.2) | 19 sync: 19 meta: 0 | 15/19 (79%) | 5-year OS 47% | 3 | unknown | 16 | unknown |
Berger et al. | ROS-MC | 2013 | 1994-2011 | 5.4y (4.2) | 6 sync: 6 meta: 0 | 3/6 (50%) | Survival in 3/6 (50%) | 2 | Survival in 2/2 (100%) | 4 | Survival in 1/4 (25%) |
Liné et al. | CS | 2014 | 1994-2001 | 1.9y (2.6) | 3 sync: 0 meta: 3 | Unclear | Survival in 2/3 (67%) | 3 | Survival 2/3 (67%) | 0 | - |
Liné et al. | ROS-OncReg | 2020 | 2002-2012 | 6y (2.6) | 18 sync: 18 meta: 0 | 14/18 (78%) | Survival in 16/18 (89%) | 14 | Survival in 12/14 (86%) | 4 | Survival in 4/4 (100%) |